Skip to main content
main-content

01.12.2014 | Research Paper | Ausgabe 8/2014

Clinical & Experimental Metastasis 8/2014

A role for STEAP2 in prostate cancer progression

Zeitschrift:
Clinical & Experimental Metastasis > Ausgabe 8/2014
Autoren:
Helen Whiteland, Samantha Spencer-Harty, Claire Morgan, Howard Kynaston, David Hywel Thomas, Pradeep Bose, Neil Fenn, Paul Lewis, Spencer Jenkins, Shareen H. Doak
Wichtige Hinweise

Electronic supplementary material

The online version of this article (doi:10.​1007/​s10585-014-9679-9) contains supplementary material, which is available to authorized users.

Abstract

Prostate adenocarcinoma is the second most frequent cancer worldwide and is one of the leading causes of male cancer-related deaths. However, it varies greatly in its behaviour, from indolent non-progressive disease to metastatic cancers with high associated mortality. The aim of this study was to identify predictive biomarkers for patients with localised prostate tumours most likely to progress to aggressive disease, to facilitate future tailored clinical treatment and identify novel therapeutic targets. The expression of 602 genes was profiled using oligoarrays, across three prostate cancer cell lines: CA-HPV-10, LNCaP and PC3, qualitatively identifying several potential prognostic biomarkers. Of particular interest was six transmembrane epithelial antigen of the prostate (STEAP) 1 and STEAP 2 which was subsequently analysed further in prostate cancer tissue samples following optimisation of an RNA extraction method from laser captured cells isolated from formalin-fixed paraffin-embedded biopsy samples. Quantitative analysis of STEAP1 and 2 gene expression were statistically significantly associated with the metastatic cell lines DU145 and PC3 as compared to the normal prostate epithelial cell line, PNT2. This expression pattern was also mirrored at the protein level in the cells. Furthermore, STEAP2 up-regulation was observed within a small patient cohort and was associated with those that had locally advanced disease. Subsequent mechanistic studies in the PNT2 cell line demonstrated that an over-expression of STEAP2 resulted in these normal prostate cells gaining an ability to migrate and invade, suggesting that STEAP2 expression may be a crucial molecule in driving the invasive ability of prostate cancer cells.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

★ PREMIUM-INHALT
e.Med Interdisziplinär

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de. Zusätzlich können Sie eine Zeitschrift Ihrer Wahl in gedruckter Form beziehen – ohne Aufpreis.

Weitere Produktempfehlungen anzeigen
Zusatzmaterial
Supplemental Fig. 1: List of all genes screened in the oligoarray analysis. A comprehensive list of genes analysed in the oligoarray analysis displayed based on the signalling pathway array type they were positioned upon. Supplementary material 1 (DOC 91 kb)
10585_2014_9679_MOESM1_ESM.doc
Supplemental Fig. 2: Oligoarray gene spot intensities for all four cell lines. Using oligoarrays tailored to four various pathways: WNT signalling pathway, TGFβ/BMP signalling pathway, ECM and adhesion molecules, and PCa biomarkers; over 600 genes were analysed for qualitative identification of potential biomarkers of aggressive PCa. Supplementary material 2 (DOC 72 kb)
10585_2014_9679_MOESM2_ESM.doc
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 8/2014

Clinical & Experimental Metastasis 8/2014 Zur Ausgabe
  1. Das kostenlose Testabonnement läuft nach 14 Tagen automatisch und formlos aus. Dieses Abonnement kann nur einmal getestet werden.

  2. Das kostenlose Testabonnement läuft nach 14 Tagen automatisch und formlos aus. Dieses Abonnement kann nur einmal getestet werden.

Neu im Fachgebiet Onkologie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Onkologie und bleiben Sie gut informiert – ganz bequem per eMail.

Bildnachweise